Ernest Walch
Motor neurons begin to deteriorate in people with Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative condition. However, this complicated illness goes beyond the limits of the central nervous system since metabolic changes are seen at the systemic and cellular levels. The use of metabolism biomarkers in ALS is still poorly unexplored, despite the fact that research evaluating the function and effects of metabolic disturbances in ALS are multiplying quickly. In the context of ALS, we examine both existing and potential metabolic indicators in this review. Of those for which data are available, individual markers offer only a limited amount of knowledge, with the biggest shortcomings being illness specificity, lack of repeatability, and effectiveness in predicting prognosis.
Given the variety of metabolic markers available, it may be possible to overcome these restrictions and develop new diagnostic and prognostic indicators using a panel of metabolic biomarkers that complements other available biomarkers (such as those from neurophysiology, imaging, as well as CSF, blood, and urine markers).